Press Releases

The expansion cohort of our Phase I clinical trial is open to patient enrolment.

The company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.

UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.

Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Oxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced

Oxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Oxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced